Featured Press Releases

Swiss startup Enzian Pharmaceutics is developing a new tablet aimed at enhancing effectiveness and reducing side effects in cancer therapies

Swiss startup Enzian Pharmaceutics is developing a new tablet aimed at enhancing effectiveness and reducing side effects in cancer therapies

Regulus Therapeutics Progresses to Cohort 4 in Phase 1b MAD Trial of RGLS8429 for ADPKD Treatment

Regulus Therapeutics Progresses to Cohort 4 in Phase 1b MAD Trial of RGLS8429 for ADPKD Treatment

  • 06 May 2024

Regulus Therapeutics Inc. a biopharmaceutical company focused on the discovery and development of...

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

Gvoke VialDx™ (glucagon injection) Launched by American Regent

Gvoke VialDx™ (glucagon injection) Launched by American Regent

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

  • Octapharma
  • 08 Jan 2026
Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

  • Arkbio
  • 08 Jan 2026
Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

  • Novotech
  • 08 Jan 2026
Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

  • Coya Therapeutics, Inc.
  • 08 Jan 2026
RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

  • RoslinCT and BOOST Pharma
  • 07 Jan 2026
Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

  • Orum Therapeutics
  • 05 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
January   2026
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.